Tecentriq added to UK's EAMS for late-stage breast cancer

14 March 2019

In combination with chemotherapy, Tecentriq (atezolizumab) can now be used by UK patients with unresectable locally advanced or metastatic triple negative breast cancer whose tumors have PD-L1 expression of at least 1%.

Access is now possible because the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a positive scientific opinion for Roche's (ROG: SIX) immuno-oncology drug for the Early Access to Medicines Scheme (EAMS), which provides earlier availability of promising new unlicensed medicines to UK patients that have a high unmet clinical need.

Explaining why Tecentriq has received the positive opinion, an MHRA document states: “In patients with triple-negative breast cancer that has progressed to advanced stage disease, where it is locally inoperable or has spread to other parts of the body, the cancer is usually poorly responsive to chemotherapy and patient survival is a matter of months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK